GI Esophageal / Gastric

IRB #12071
A Pilot Study Using a Novel Imaging of Lymph Nodes in Patients with Locally Advanced Esophageal Cancer Using Ferumoxytol Enhanced MRI

Localized

HER 2+

1st Line

No Trials Currently Available

2nd Line

IRB #15349
Keynote-181
A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy

HER 2-

1st Line

IRB #15706
EMR100070-007: Phase III open-label, of maintenance therapy with avelumab versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction

2nd Line

IRB #15349
Keynote-181
A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy

http://www.ohsu.edu/research/rda/so/knight.php